Introduction
Mucormycosis is a low-prevalence fungal infection with high mortality, primarily affecting immunocompromised patients, such as diabetics and COVID-19 patients. In the maxillofacial region, it presents with facial pain, swelling, and ulcers, making early diagnosis and timely treatment crucial. The objective of this study is to perform a structured literature review on the implications of mucormycosis in maxillofacial surgery, focusing on its epidemiology, diagnostic approaches, and treatment strategies.
Materials and Methods
A narrative literature review was conducted using the keywords “Mucormycosis” AND “Maxillofacial Surgery” across the databases PubMed, SciELO, Scopus, ScienceDirect, and Google Scholar. Relevant articles published in the last 10 years, from January 2015 to March 2025, were included, focusing on the epidemiology, diagnosis, and treatment of mucormycosis in maxillofacial surgery.
Results
Rhino-orbito-cerebral mucormycosis (ROCM) is the most common form in maxillofacial surgery, particularly in patients with diabetes, those treated with immunosuppressive corticosteroids, and those affected by COVID-19. Diagnosis involves clinical history, imaging, and histopathological analysis, complemented by pharmacological and surgical treatments.
Conclusion
Mucormycosis is a complex and challenging condition in maxillofacial surgery, with high mortality. A multidisciplinary approach combining early diagnosis, surgical treatment, and appropriate antifungal therapy is essential to improve survival and reduce the sequelae of the infection.
扫码关注我们
求助内容:
应助结果提醒方式:
